Potential new medical therapies for diabetic retinopathy: Protein kinase C inhibitors

American Journal of Ophthalmology

Volumn 133, Issue 5, 2002, Pages 693-698

  Frank, Robert N ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE TRIPHOSPHATE; ALDOSE REDUCTASE INHIBITOR; AMINOGUANIDINE; DIACYLGLYCEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ISOPROTEIN; LISINOPRIL; MEMBRANE RECEPTOR; OCTREOTIDE; PEGVISOMANT; PROTEIN KINASE C BETA; PROTEIN KINASE C INHIBITOR; SORBINIL; TOLRESTAT; VASCULOTROPIN;

BLOOD EYE BARRIER; CELL PROLIFERATION; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HYPERGLYCEMIA; HYPOXEMIA; ION TRANSPORT; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REMISSION; RETINA; RETINA MACULA EDEMA; REVIEW; TREATMENT OUTCOME;

EID: 0036247969     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(02)01321-1     Document Type: Editorial

References (45)

1. Hypophysectomy for diabetic angiopathy: A controlled clinical trial
2. Preliminary report on effects of photocoagulation therapy
3. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report No. 1
4. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy
5. How effective are treatments for diabetic retinopathy?
6. The effect of intensive treatment of diabetes in the development and progression of long-term complications in insulin-dependent diabetes
7. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
8. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
9. Effects of aspirin treatment on diabetic retinopathy. ETDRS Report Number 8
10. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy
11. Hyperglycemic pseudohypoxia and diabetic complications
12. Pharmacological inhibition of diabetic retinopathy: Aminoguanidine and aspirin
13. An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia
14. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II)
15. A curious stopping rule from Hoechst Marion Roussel
16. Early closure of European Pimagedine Trial
17. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes.EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus
18. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: A randomized controlled study
19. Four risk factors for severe visual loss in diabetic retinopathy. The third report from the Diabetic Retinopathy Study
20. The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy
21. Protein phosphorylation and neuronal function
22. Protein phosphorylation and dephosphorylation in mammalian central nervous system
23. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia
24. Tissue and cellular distribution of the extended family of protein kinase C isoenzymes
25. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro
26. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders
27. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy
28. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy
29. Localization of vascular endothelial growth factor in human retina and choroid
30. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor
31. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth
32. The biology of vascular endothelial growth factor
33. Vascular endothelial growth factor (VEGF) and its receptors
34. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells
35. Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy
36. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate
37. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins
38. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy
39. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. V. Relationship between protein kinase C and ATPases
40. β1 overexpression augments phorbol ester-induced increases in endothelial permeability
41. (S)-13-[(Dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16,21- dimetheno-1H,13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]- oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: Isozyme selective inhibitors of protein kinase Cβ
42. Inhibition of intraocular neovascularization due to retinal ischemia in pigs by PKCβ inhibition with LY333531
43. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor
44. Immunodeficiency in protein kinase Cβ-deficient mice
45. A role for the beta isoform of protein kinase C in fear conditioning